Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEPA Hepion Pharmaceuticals	$0.05 -4.5%	$0.06	$0.03 ▼ $0.08	$628K	1.52	85,745 shs	79,733 shs
PBLA Panbela Therapeutics	$0.16	$0.18	$0.05 ▼ $0.47	$767K	1.33	16,227 shs	501 shs
VINC Vincerx Pharma	$0.04 +4.5%	$0.04	$0.03 ▼ $17.00	$206K	1.71	571,284 shs	365,050 shs
ZVSA ZyVersa Therapeutics	$0.14 -5.7%	$0.39	$0.11 ▼ $3.37	$1.10M	0.75	3.35 million shs	40,940 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEPA Hepion Pharmaceuticals	-4.52%	-12.86%	-14.22%	-28.33%	-99.86%
PBLA Panbela Therapeutics	0.00%	0.00%	0.00%	-33.40%	-56.38%
VINC Vincerx Pharma	+4.51%	+1.81%	-28.23%	-20.40%	-99.74%
ZVSA ZyVersa Therapeutics	-5.71%	-10.23%	-41.02%	-74.33%	-96.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HEPA Hepion Pharmaceuticals	0.5907 of 5 stars	0.0	5.0	0.6	0.0	0.6
PBLA Panbela Therapeutics	0.3281 of 5 stars	0.0	5.0	0.6	0.0	0.0
VINC Vincerx Pharma	2.618 of 5 stars	3.5	3.0	0.6	1.7	1.3
ZVSA ZyVersa Therapeutics	0.6146 of 5 stars	0.0	4.0	1.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEPA Hepion Pharmaceuticals	0.00	N/A	N/A	N/A
PBLA Panbela Therapeutics	0.00	N/A	N/A	N/A
VINC Vincerx Pharma	3.00	Buy	$40.00	101,422.84% Upside
ZVSA ZyVersa Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.29 per share	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	($18.37) per share	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	$10.50 per share	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	$3.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEPA Hepion Pharmaceuticals	-$48.93M	-$219.00	N/A	∞	N/A	N/A	-812.56%	-207.31%	N/A
PBLA Panbela Therapeutics	-$25.26M	-$71.13	N/A	∞	N/A	N/A	N/A	-302.61%	N/A
VINC Vincerx Pharma	-$40.16M	-$20.60	N/A	N/A	N/A	N/A	-248.33%	-132.73%	11/10/2025 (Estimated)
ZVSA ZyVersa Therapeutics	-$9.41M	N/A	0.00	N/A	N/A	N/A	-109.54%	-43.95%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEPA Hepion Pharmaceuticals	N/A	1.30	1.30
PBLA Panbela Therapeutics	N/A	0.26	0.26
VINC Vincerx Pharma	N/A	2.17	2.17
ZVSA ZyVersa Therapeutics	N/A	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HEPA Hepion Pharmaceuticals	17.24%
PBLA Panbela Therapeutics	4.37%
VINC Vincerx Pharma	44.02%
ZVSA ZyVersa Therapeutics	3.91%

Insider Ownership

Company	Insider Ownership
HEPA Hepion Pharmaceuticals	0.06%
PBLA Panbela Therapeutics	0.01%
VINC Vincerx Pharma	15.60%
ZVSA ZyVersa Therapeutics	0.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HEPA Hepion Pharmaceuticals	20	11.44 million	6.63 million	No Data
PBLA Panbela Therapeutics	6	4.86 million	4.86 million	Not Optionable
VINC Vincerx Pharma	60	5.23 million	1.89 million	Not Optionable
ZVSA ZyVersa Therapeutics	2	7.94 million	4.86 million	Not Optionable

VINC, PBLA, HEPA, and ZVSA Headlines

Recent News About These Companies

ZyVersa Therapeutics Reports Financial Challenges Amid Nasdaq Delisting

August 20 at 4:54 AM | msn.com

ZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last year

August 14, 2025 | msn.com

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address ...

August 14, 2025 | bakersfield.comB

ZyVersa Therapeutics highlights data on role of lipotoxicity in DKD

August 14, 2025 | msn.com

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

August 14, 2025 | globenewswire.com

ZyVersa Therapeutics Activates First Clinical Site for Phase 2a Trial of VAR 200 in Diabetic Kidney Disease and Reports Progress in Product Development

August 13, 2025 | quiverquant.comQ

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

August 13, 2025 | globenewswire.com

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

July 21, 2025 | globenewswire.com

ZyVersa Touches 52-Week Low; Nasdaq to Suspend Trading Thursday

July 16, 2025 | marketwatch.com

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | Morningstar

July 9, 2025 | morningstar.comM

ZyVersa’s VAR 200 approved for emergency use in rare kidney disease

July 9, 2025 | uk.investing.com

ZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis - Nasdaq

July 9, 2025 | nasdaq.com

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?

July 8, 2025 | benzinga.com

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

July 8, 2025 | globenewswire.com

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII Amyloidosis

July 8, 2025 | finanznachrichten.de

ZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis

July 8, 2025 | quiverquant.comQ

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediatorâ„¢Â VAR 200 in a Patient with ApoCII Amyloidosis

July 8, 2025 | globenewswire.com

ZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200 - Nasdaq

June 27, 2025 | nasdaq.com

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol ...

June 26, 2025 | morningstar.comM

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients ...

June 26, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VINC, PBLA, HEPA, and ZVSA Company Descriptions

Hepion Pharmaceuticals NASDAQ:HEPA

$0.05 0.00 (-4.52%)

As of 08/22/2025 02:15 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Panbela Therapeutics NASDAQ:PBLA

$0.16 0.00 (0.00%)

As of 08/21/2025 11:24 AM Eastern

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Vincerx Pharma NASDAQ:VINC

$0.04 +0.00 (+4.51%)

As of 08/22/2025 03:39 PM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

ZyVersa Therapeutics NASDAQ:ZVSA

$0.14 -0.01 (-5.71%)

As of 08/22/2025 03:17 PM Eastern

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time